Oncological impact of perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy: Do we need to consider storage time of blood units, donor age, or gender matching?
- PMID: 38053445
- DOI: 10.1111/trf.17618
Oncological impact of perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy: Do we need to consider storage time of blood units, donor age, or gender matching?
Abstract
Background: The oncological impact of perioperative blood transfusions (PBTs) of patients undergoing radical cystectomy (RC) because of bladder cancer (BCa) has been a controversial topic discussed in recent years. The main cause for the contradictory findings of existing studies might be the missing consideration of the storage time of red blood cell units (BUs), donor age, and gender matching.
Study design and methods: We retrospectively analyzed BCa patients who underwent RC in our department between 2004 and 2021. We excluded patients receiving BUs before RC, >10 BUs, or RC in a palliative setting. We assessed the effect of blood donor characteristics and storage time on overall survival (OS) and cancer-specific survival (CSS) through univariate and multivariable Cox regression analysis. We also performed a propensity score matching with patients who received BUs and patients who did not on a 1:1 ratio.
Results: We screened 1692 patients and included 676 patients for the propensity score matching. In the multivariable analysis, PBT was independently associated with worse OS and CSS (p < .001). Postoperative transfusions were associated with better OS (p = .004) and CSS (p = .008) compared to intraoperative or mixed transfusions. However, there was no influence of blood donor age, storage time, or gender matching on prognosis.
Discussion: In our study of BCa patients undergoing RC, we demonstrate that PBT, especially if administered intraoperatively, is an independent risk factor for a worse prognosis. However, storage time, donor age, or gender matching did not negatively affect oncological outcomes. Therefore, the specific selection of blood products does not promise any benefits.
© 2023 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
References
REFERENCES
-
- Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82-104.
-
- Bukavina L, Mishra K, Mahran A, Shekar A, Sheyn D, Slopnick E, et al. Gender disparity in cystectomy postoperative outcomes: propensity score analysis of the National Surgical Quality Improvement Program Database. Eur Urol Oncol. 2021;4:84-92.
-
- Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391:2525-2536.
-
- Wijburg CJ, Michels CTJ, Hannink G, Grutters JPC, Rovers MM, Alfred Witjes J, et al. Robot-assisted radical cystectomy versus open radical cystectomy in bladder cancer patients: a multicentre comparative effectiveness study. Eur Urol. 2021;79:609-618.
-
- Uysal D, Egen L, Grilli M, Wessels F, Lenhart M, Michel MS, et al. Impact of perioperative blood transfusions on oncologic outcomes after radical cystectomy: a systematic review and meta-analysis of comparative studies. Surg Oncol. 2021;38:101592.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
